Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma

NCT00438581 is registered in ClinicalTrials.gov with McGill University as lead sponsor.

NCT NCT00438581
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00438581 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Non-Randomized Study Combining Yttrium 90 Ibritumomab Tiuxetan (Zevalin) With High-Dose Chemotherapy Prior to Autologous Stem Cell Transplantation in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma
Lead sponsor
McGill University
Phase
Phase 2
Overall status
Unknown status
Start date
March 31, 2007
Completion date
Not reported
Enrollment
40
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin's lymphoma